The U.S. Food and Drug Administration granted approval to Myfembree, Myovant Sciences and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Patients receiving the therapy under the newly approved indication can take the medicine for up to 24 months. 

Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma. 

A follow-up study of 33 people who received Moderna Inc.’s Covid-19 vaccine in early trials show the antibodies it induced are still present six months after the second dose.

The Covid-19 vaccine from Pfizer Inc. and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on March 8.

Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.

The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.

NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to the company’s CSO James Trager at the virtual CAR-TCR Summit – Europe.

Novo Nordisk is positioning the company’s type 2 diabetes treatment Ozempic (semaglutide) as an anti-obesity treatment, as data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 analog significantly reduced weight in patients over the course of 68 weeks.

In a paper published in Alzheimer’s and Dementia, a team of researchers called for more prospective studies that will look into the impact COVID-19 has on brain functioning, given the disease has been frequently associated with neurologic symptoms such as seizures and psychosis.

The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.